Cassava Sciences, Inc.

SAVA

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
February 10, 2025

Days Left:
51

calendar

Cassava Sciences, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, defendants provided investors with material information concerning Cassava’s leading drug candidate, simufilam. Defendants’ statements included, among other things, clear confidence in simufilam’s ability to treat Alzheimer’s Disease. On November 25, 2024, Cassava released topline results for the first of its two ongoing Phase 3 studies on simufilam, the “ReThink-ALZ” study. The results indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo. Following this news, the price of Cassava’s common stock declined dramatically. From a closing market price of $26.48 per share on November 22, 2024, Cassava’s stock price fell to $4.30 per share on November 25, 2024, a decline of about 83.76% in the span of just a single day.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Cassava Sciences, Inc. purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Cassava Sciences, Inc. during the relevant time frame, you have until February 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join
SUI Sun Communities, Inc. February 10, 2025 Join
SAVA Cassava Sciences, Inc. February 10, 2025 Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join